Ann: Appendix 3Y - G Rezos, page-49

Agree with the comments on NASDAQ listing.

One company that comes to mind is Prima Biomed (ASX: PRR). It was launched with much fanfare on the NASDAQ in April 2012. At the time, it was trading around $0.20 on the ASX.

Just two weeks later, as it traded around $0.16 on the ASX, one PRR shareholder commented

If the Nasdaq listing was meant to put a rocket under the SP it looks like the rocket was built by North Korea as its barely launched before crashing back down.

It has received multiple NASDAQ deficiency notices since (issued when price isn’t maintained over US$1.00).

In late 2015, when PRR was trading at $0.055 on the ASX, one poster reflected

When it was first mentioned 4 or 5 yrs ago about listing on Nasdaq it was greeted with raucous support and everyone was drooling about how much money we would all make out of it.......Anyway it turned out to be a bit of a fizzer…

PRR currently trades on the ASX at $0.023.

Personally, I would prefer to see the company focus on building its product portfolio, its markets, its sales and, most importantly, its profitability. That is how the company will attract wider interest and institutional investment. To use a familiar quotation, “If you build it, they will come”.